Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-06-09
2000-02-22
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514314, 514326, 544333, 546167, 546211, 5483641, 5483644, A01N 4354, C07D40100, C07D23102, C07D23100
Patent
active
060280727
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating inflammation and inflammation-associated disorders, such as arthritis.
BACKGROUND OF THE INVENTION
Prostaglandins play a major role in the inflammation process and the inhibition of prostaglandin production, especially production of PGG.sub.2, PGH.sub.2 and PGE.sub.2, has been a common target of antiinflammatory drug discovery. However, common non-steroidal antiinflammatory drugs (NSAIDs) that are active in reducing the prostaglandin-induced pain and swelling associated with the inflammation process are also active in affecting other prostaglandin-regulated processes not associated with the inflammation process. Thus, use of high doses of most common NSAIDs can produce severe side effects, including life threatening ulcers, that limit their therapeutic potential. An alternative to NSAIDs is the use of corticosteroids, which have even more drastic side effects, especially when long term therapy is involved.
Previous NSAIDs have been found to prevent the production of prostaglandins by inhibiting enzymes in the human arachidonic acid/prostaglandin pathway, including the enzyme cyclooxygenase (COX). The recent discovery of an inducible enzyme associated with inflammation (named "cyclooxygenase-2 (COX-2)" or "prostaglandin G/H synthase II") provides a viable target of inhibition which more effectively reduces inflammation and produces fewer and less drastic side effects.
The references below that disclose antiinflammatory activity, show continuing efforts to find a safe and effective antiinflammatory agent. The novel pyrazoles disclosed herein are such safe and also effective antiinflammatory agents furthering such efforts. The invention's compounds are found to show usefulness in vivo as antiinflammatory agents with minimal side effects. The substituted pyrazolyl compounds disclosed herein preferably selectively inhibit cyclooxygenase-2 over cyclooxygenase-1.
Pyrazoles have been described for use in the treatment of inflammation. U.S. Pat. No. 5,134,142 to Matsuo et al. describes 1,5-diaryl pyrazoles, and specifically, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl pyrazole, as having anti-inflammatory activity. Co-pending applications Ser. Nos. 8/160,553 and 8/160,594 describe substituted 1,5-substituted pyrazoles for the treatment of inflammation.
U.S. Pat. No. 3,254,093, to Huisgen et al, describes a process for preparing pyrazoles. Ethyl [1-benzyl-3-phenyl-pyrazole]carboxylic acid is described.
WO 8300330, published Feb. 3, 1983, describes a process for the preparation of 3,4-diphenyl-5-methyl pyrazolyl derivatives. WO 9219615, published Nov. 12, 1992, describes pyrazolyl compounds having fungicidal properties. U.S. Pat. No. 4,968,681, to Hubsch et al., describes (pyrazol-5-yl)hydroxylamines as agents for the treatment of lipoproteinaemia.
U.S. Pat. No. 3,984,431, to Gueremy and Renault, describes derivatives of pyrazolyl-5-acetic acid as having antiinflammatory activity. Specifically, [1-isobutyl-3,4-diphenyl-1H-pyrazol-5-yl]acetic acid is described.
The invention's pyrazolyl compounds are found to show usefulness in vivo as antiinflammatory agents with minimal side effects.
DESCRIPTION OF THE INVENTION
A class of substituted pyrazolyl compounds useful in treating inflammation-related disorders is defined by Formula I: ##STR2## wherein R.sup.1 is selected from hydrido, alkyl, alkenyl, alkynyl, haloalkyl, aralkyl, heterocycloalkyl, heteroaralkyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, alkylaminocarbonylalkyl, N-hydroxyaminocarbonylalkyl, N-hydroxy-N-alkyl-aminocarbonylalkyl, arylaminocarbonylalkyl and aminocarbonylalkyl; cycloalkyl, cycloalkenyl and heterocyclo, wherein R.sup.2 and R.sup.3 are optionally substituted at a substitutable position with one or more radicals independently selected from alkylsulfonyl, aminosulfonyl, haloalkylsulfonyl, ha
REFERENCES:
patent: 5559137 (1996-09-01), Adams et al.
patent: 5700816 (1997-12-01), Isakson et al.
Kramer Steven W
Lee Len F
Penning Thomas D
Talley John J
Bulock Joseph W.
G. D. Searle & Co.
Ngo Tamthom T.
Shah Mukund J.
LandOfFree
3,4-substituted pyrazoles for the treatment of inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,4-substituted pyrazoles for the treatment of inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,4-substituted pyrazoles for the treatment of inflammation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-520707